<DOC>
	<DOCNO>NCT00003336</DOCNO>
	<brief_summary>RATIONALE : Umbilical cord blood transplantation may allow doctor give high dos chemotherapy radiation therapy kill cancer cell . PURPOSE : This phase II trial study well umbilical cord blood transplantation work treat patient severe aplastic anemia , malignant thymoma , myelodysplasia .</brief_summary>
	<brief_title>Pilot Study Of Unrelated UCB Transplant Non-Malignant Hematologic Conditions</brief_title>
	<detailed_description>OBJECTIVES : - Determine rate durable engraftment patient severe aplastic anemia , myelodysplastic syndrome , inborn error metabolism , inherit hematopoietic disorder , refractory medical management , undergo high-dose chemoradiotherapy follow unrelated cord blood ( UCB ) transplantation . - Evaluate rate quality immunologic reconstitution patient population . OUTLINE : Patients stratify accord weight ( 45 kg v 45 kg ) . Patients receive high-dose chemotherapy and/or radiotherapy condition regimen begin 6-9 day umbilical cord blood transplant ( UCBT ) . The regimen vary accord underlie cause anemia , could include busulfan , cyclophosphamide melphalan , anti-thymocyte globulin methylprednisolone , and/or radiation therapy . One day condition regimen complete , patient receive UCBT . Patients follow weekly 3 month , 6 month , every 6 month 2.5 year , annually thereafter . PROJECTED ACCRUAL : A total 4-90 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis severe aplastic anemia base bone marrow cellularity le 20 % Must meet least two follow criterion : Granulocyte count le 500/mm^3 Platelet count le 20,000/mm^3 Reticulocyte count le 50,000/mm^3 Following etiology eligible : Fanconi 's anemia Hypoplastic leukemia Monosomy 7 Drug exposure ( chloramphenicol , NSAIDS ) Viral exposure ( EBV , hepatitis , parvovirus , HIV ) Nutritional deficiency Thymoma Paroxysmal nocturnal hemoglobinuria Amegakaryocytic thrombocytopenia OR Histologically confirm myelodysplastic syndrome ( MDS ) refractory medical management cytogenic abnormality predictive transformation acute leukemia , include 5q , 7q , monosomy 7 , trisomy 8 The following etiology eligible : Refractory anemia Refractory anemia ring sideroblast De novo primary MDS Therapyrelated secondary MDS OR Confirmed diagnosis inherit hematopoietic disorder refractory medical management Following etiology eligible : Severe combine immunodeficiency Familial erythrophagocytic lymphohistiocytosis WiskottAldrich syndrome Kostmann 's syndrome ( infantile histiocytosis ) Chronic granulomatous disease Leukocytic adhesion deficiency ChediakHigashi syndrome Paroxysmal nocturnal hemoglobinuria Fanconi 's anemia Dyskeratosis congenita DiamondBlackfan anemia Amegakaryocytic thrombocytopenia Osteopetrosis Gaucher 's disease LeschNyhan syndrome Mucopolysaccharidoses Lipodoses Autologous haploidentical related peripheral blood stem cell available backup Serologically match umbilical cord blood unit available New York Blood Center 's Placental Blood Project , acceptable umbilical cord blood registry PATIENT CHARACTERISTICS : Age : 55 Performance status : Zubrod 01 Karnofsky 80100 % Life expectancy : At least 3 month Hematopoietic : See Disease Characteristics Hepatic : ALT/AST great 4 time normal Bilirubin great 2.0 mg/dL Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 50 mL/min Cardiovascular : Normal cardiac function echocardiogram radionuclide scan Shortening fraction ejection fraction least 80 % normal age NonFanconi patient acquire congenital cardiomyopathy may receive melphalan substitute cyclophosphamide Pulmonary : FVC FEV_1 least 60 % predict age DLCO least 60 % predict adult patient Other : No active concurrent malignancy No active infection Not pregnant nursing HIV negative Must available serologic match Umbilical Cord Blood Unit ( UCBU ) New York Blood Center 's Placental Blood Project , acceptable Umbilical Cord Blood ( UCB ) registry PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent cytotoxic chemotherapy Endocrine therapy : No concurrent immunosuppressive medication Radiotherapy : No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>